

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

NCT07461545

Status	RECRUITING
Phase	Not Applicable
Sponsor	Northern Jiangsu People's Hospital
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (10)

- A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
- Splenomegaly with secondary hypersplenism.
- No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.
- Underwent laparoscopic splenectomy at our center.
- Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.
- ... and 5 more (see full listing online)

Exclusion (10)

- Hepatocellular carcinoma or any other malignancy.
- Hypercoagulable state other than the liver disease related.
- DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
- Portal hypertension bleeding .
- Child - Pugh C
- ... and 5 more (see full listing online)

Locations (1 total)

Clinical Medical College, Yangzhou, Jiangsu, China